ALMS
Alumis Inc. Common StockNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
7.62
P/S
112.34
EV/EBITDA
-6.40
DCF Value
$1.18
FCF Yield
-13.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.4%
Operating Margin
-1837.4%
Net Margin
-1011.7%
ROE
-72.7%
ROA
-59.1%
ROIC
-124.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.9M | $-92.9M | $-0.89 |
| FY 2025 | $24.1M | $-243.3M | $-2.86 |
| Q3 2025 | $2.1M | $-110.8M | $-1.06 |
| Q2 2025 | $2.7M | $59.3M | $0.77 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-2.13
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.